The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance.
 
Hirotsugu Kenmotsu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst)
 
Fumikazu Sakai
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Janssen; Merck Serono; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kyorin; Shionogi
Research Funding - Bayer (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Fuji Pharma (Inst); Toshiba (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Kyorin; Shionogi
 
Terufumi Kato
Employment - Lilly (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); Parexel (Inst); Pfizer (Inst); Quintiles (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Masahiko Kusumoto
Consulting or Advisory Role - Ono Pharmaceutical
 
Tomohisa Baba
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Boston Scientific; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Boston Scientific; Shionogi
 
Kazuyoshi Kuwano
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Meiji Seika Kaisha; Shionogi
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Kyorin (Inst); Meiji Seika Kaisha (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Akihiko Gemma
Speakers' Bureau - Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EPS Holdings; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Showa Yakuhin Kako; SymBio Pharmaceuticals
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Merck Sharp & Dohme (Inst); Nippon Boehringer Ingelheim (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yoichi Nakanishi
Honoraria - Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer
Research Funding - Asahi Kasei; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Pfizer
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Fujifilm; Janssen; Kyorin; Kyowa Hakko Kirin; Lilly; M3; MSD; Nippon Boehringer Ingelheim; Novartis; Oncolab; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Chugai Pharma; MSD; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Research Funding - AC Medical; AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Kyorin; Kyowa Hakko Kirin; Maruho; Meiji Seika Kaisha; MSD; Nippon Boehringer Ingelheim; Ono Pharmaceutical; PAREXEL; Pfizer; Quintiles; Shionogi; Taiho Pharmaceutical
 
Yoshihiko Ito
Employment - Ono Pharmaceutical
 
Yasuhiro Tahara
Employment - Ono Pharmaceutical
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca